Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles

GettyImages-1212665265

Why Is Everyone Talking About OPKO Health Stock?

The pharmaceutical and diagnostics specialist ran into some SEC-related controversy in 2018; now, it's a major player in the fight against COVID-19.


GettyImages-1058568562

2 Marijuana Stocks That Could Be Millionaire Makers

Innovative Industrial Properties and Planet 13 have the potential to be big winners.


GettyImages-1079920024

3 Top Restaurant Stocks to Buy in April

Here are two steak houses and a dominant chicken wing franchise for investors to bite into.


GettyImages-996271418

Immunomedics Halts Phase 3 Trial of Breast Cancer Drug Because of Compelling Efficacy

Sacituzumab govitecan has proven effective against triple-negative breast cancer.


GettyImages-450806655

2 Stocks to Get You Started Investing in 2020

Are you ready to jump in and make your first stock purchases. Here are some tips.

GettyImages-1027081942

2 Top Stocks That Aren't On Wall Street's Radar

Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.


GettyImages-482727687

Why Did Amarin's Stock Fall Off a Cliff?

Amarin's stock dropped 70% after its patent for Vascepa was invalidated by a federal judge.


GettyImages-1164083375

3 High-Growth Stocks That Could Soar

When the world recovers from the COVID-19 pandemic, these three stocks should rebound first.


GettyImages-1132848597

Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial

The company's depression drug AXS-05 failed to meet its primary endpoints in the study, although it did hit the secondary endpoints.


Asset 5-100

About to Buy Penny Stocks? Look at These 3 Companies First

Here are three stocks that are all down over 60% thanks to COVID-19. Will they bounce back?

GettyImages-1140075616

SmileDirectClub Will Start Making Face Shields for Doctors and Nurses

To help out during the COVID-19 pandemic, the teeth-straightening specialist will devote some of its 3-D printers to making protective gear for medical professionals.


GettyImages-679798726

Novavax Gets a Big Win for Its Flu Vaccine in Phase 3 Trial

After the biotech company needed a 1-for-20 reverse stock split last year to avoid being delisted, Novavax has hit a home run with NanoFlu.


GettyImages-483688202

My Top 7 Stocks to Buy in March's Stock Market Crash

Some amazing stocks are on sale right now.


GettyImages-1206809967

FDA Issues Guidance for Clinical Trials During COVID-19 Pandemic

Efforts to stem the coronavirus outbreak are liable to disrupt the protocols of a lot of drug trials.


GettyImages-840206400

3 Stocks to Buy After the Coronavirus Crash

These companies should bounce back strong when the market finally recovers from the panic over COVID-19.

GettyImages-1148621172

2 Winning Stocks to Buy in the Coronavirus Panic

While the spread of COVID-19 has destroyed billions of dollars of market value, stocks in healthcare companies that are fighting the virus continue to advance.


GettyImages-1186936189

Regeneron and Sanofi Start Human Trials of Arthritis Drug as Possible COVID-19 Treatment

Kevzara is being tested in a phase 2/3 trial to see if it's effective against the novel coronavirus.


GettyImages-1202306007

Teladoc Health Reports 50% Spike in Daily Patient Visits

The telemedicine leader's stock is up 53% so far in 2020.


GettyImages-1201549319

Under Questioning, CDC Director Agrees To Provide Free Testing for COVID-19, Regardless Of Insurance

While testifying before Congress, CDC chief Dr. Robert Redfield confirmed his agency will pay for COVID-19 testing on people without insurance.


GettyImages-942116434

Why Arrowhead Pharmaceuticals Shares Dropped 15% in February

After a stellar 2019, the biotech stock has lost 47% so far in 2020.